BackIntra-Cellular Therapies Overview

Intra-Cellular Therapies Current Cash

Intra-Cellular Therapies's current cash is $310M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$306.95M
107.72% YoYΔ $159.18M vs prior year quarter

Peer average

Loading

Intra-Cellular Therapies Current Cash History

Loading

Intra-Cellular Therapies vs. peers: Current Cash Comparison

Loading

Intra-Cellular Therapies Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Intra-Cellular Therapies (ITCI) FAQ

As of the most recent data (December 2024), ITCI shows a current cash of $310M. That compares with $150M in the prior-year period — up 107.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ITCI's current cash is now $310M (was $150M) — a 107.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Intra-Cellular Therapies is outperforming or lagging.

Tracking ITCI's current cash over time shows whether Intra-Cellular Therapies is scaling, shrinking, or reshaping that part of the business. The current reading is $310M That compares with $150M in the prior-year period — up 107.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Intra-Cellular Therapies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $310M) with ownership activity and broader fundamentals.

Intra-Cellular Therapies's current cash is $310M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.